Back to Search Start Over

Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)

Authors :
Achim Woeckel
Marcus Schmidt
Maria Blettner
Inga Bekes
Hiltrud Merzenich
Heinz Schmidberger
Lukas Schwentner
Wolfgang Janni
Thomas Wiegel
Dan Baaken
Detlef Bartkowiak
Daniel Wollschläger
Source :
Breast Cancer Research and Treatment
Publication Year :
2021
Publisher :
Springer Science and Business Media LLC, 2021.

Abstract

Purpose Radiotherapy (RT) was identified as a risk factor for long-term cardiac effects in breast cancer patients treated until the 1990s. However, modern techniques reduce radiation exposure of the heart, but some exposure remains unavoidable. In a retrospective cohort study, we investigated cardiac mortality and morbidity of breast cancer survivors treated with recent RT in Germany. Methods A total of 11,982 breast cancer patients treated between 1998 and 2008 were included. A mortality follow-up was conducted until 06/2018. In order to assess cardiac morbidity occurring after breast cancer treatment, a questionnaire was sent out in 2014 and 2019. The effect of breast cancer laterality on cardiac mortality and morbidity was investigated as a proxy for radiation exposure. We used Cox Proportional Hazards regression analysis, taking potential confounders into account. Results After a median follow-up time of 11.1 years, there was no significant association of tumor laterality with cardiac mortality in irradiated patients (hazard ratio (HR) for left-sided versus right-sided tumor 1.09; 95% confidence interval (CI) 0.85–1.41). Furthermore, tumor laterality was not identified as a significant risk factor for cardiac morbidity (HR = 1.05; 95%CI 0.88–1.25). Conclusions Even though RT for left-sided breast cancer on average incurs higher radiation dose to the heart than RT for right-sided tumors, we found no evidence that laterality is a strong risk factor for cardiac disease after contemporary RT. However, larger sample sizes, longer follow-up, detailed information on individual risk factors and heart dose are needed to assess clinically manifest late effects of current cancer therapy.

Details

ISSN :
15737217 and 01676806
Volume :
191
Database :
OpenAIRE
Journal :
Breast Cancer Research and Treatment
Accession number :
edsair.doi.dedup.....bfc0bf6825fa9ee571d16c47b0353e6b
Full Text :
https://doi.org/10.1007/s10549-021-06412-3